Argos Therapeutics Breaks Ground on Biomanufacturing Facility
The new Argos biomanufacturing facility in North Carolina will include automated production using the company's Arcelis technology.
Argos Therapeutics, a biopharmaceutical company focused on personalized immunotherapies, broke ground on a new 100,000-square-foot biomanufacturing facility in the Research Triangle Park area in North Carolina. The facility is expected to open in the first quarter of 2016.
The facility will support automated production of the company's Arcelis-based personalized immunotherapy product candidates for the treatment of cancer and infectious disease. The Arcelis process uses a small tumor or blood sample along with the patient’s own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The process uses RNA isolated from the patient´s disease sample to program dendritic cells to target disease antigens. The company's lead oncology product candidate, AGS-003, is currently being evaluated in a Phase III clinical trial for the treatment of metastatic renal cell carcinoma.
Source: Argos Therapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
